|Slideshows|September 9, 2019

Bipolar Disorder: Psychosis, Mania, and Additional Research

Call for better first-episode mania care, brain activation patterns predict risk, what’s important about atypical antipsychotics- find concise summaries of these and other key developments here.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

New Analysis of BXCL501 At-Home Administration Shows Reduction of Agitation in Bipolar and Schizophrenia

ByJessica Walters

May 29th 2026

The Significant Presence of Comorbidities in Bipolar Depression: Insights From Mark Zimmerman, MD

ByMark Zimmerman, MD

May 27th 2026

Bipolar Disorder With Mixed Features: Recognition and Treatment, With Roger McIntyre, MD, at APA

ByJessica Walters

May 20th 2026

New Data From IMPACT-TD Registry: Only 23% of Young Adults With Mood Disorders and Tardive Dyskinesia Symptoms Are Formally Diagnosed

ByLeah Kuntz

May 18th 2026

Decision-Making and Risk Assessment in Perinatal Psychopharmacology

ByVeerle Bergink, MD

May 17th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Bipolar Disorder: Psychosis, Mania, and Additional Research

Related Content

New Analysis of BXCL501 At-Home Administration Shows Reduction of Agitation in Bipolar and Schizophrenia

The Significant Presence of Comorbidities in Bipolar Depression: Insights From Mark Zimmerman, MD

Bipolar Disorder With Mixed Features: Recognition and Treatment, With Roger McIntyre, MD, at APA

New Data From IMPACT-TD Registry: Only 23% of Young Adults With Mood Disorders and Tardive Dyskinesia Symptoms Are Formally Diagnosed

Decision-Making and Risk Assessment in Perinatal Psychopharmacology

Latest CME

Southern California Psychiatry Conference

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Trending on Psychiatric Times

FDA Issues CRL for CTx-1301 for Treatment of ADHD

Insights Into Mechanism-Based Biomarkers for Psychosis Prediction from Kim Do, PhD

New Name, New Path for Psychiatry: The Future of the DSM

Nonpharmacological Augmentation of Ketamine, Neuroplasticity, and Behavioral Therapy

Endangered Education: Psychiatric Professional Degrees Under Attack